...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research >Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate.
【24h】

Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate.

机译：利塞膦酸盐治疗3年和5年后，来自人类c c活检的小梁骨的骨材料特性。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Long-term effects of risedronate on bone mineral maturity/crystallinity and collagen cross-link ratio in triple iliac crest biopsies of osteoporotic women were evaluated. In this double-blinded study, 3- and 5-year treatment with risedronate arrested the tissue aging encountered in untreated osteoporosis and in osteoporosis treated with other antiresorptives. This effect may be contributing to risedronate's antifracture efficacy. INTRODUCTION: Risedronate is widely used in the treatment of osteoporosis. It reduces bone turnover, increases BMD, and decreases fracture risk. To date, there are no data available on the long-term effects of risedronate on bone material properties in humans. MATERIALS AND METHODS: Osteoporotic women enrolled in the VERT-NA trial received either risedronate (5 mg/day, orally) or placebo for up to 5 years. All subjects received calcium. They also received vitamin D supplementation if deficient at baseline. Triple iliac crest biopsies were collected from a subset of these subjects at baseline, 3 years, and 5 years. Mineral maturity/crystallinity and collagen cross-link ratio was measured in these biopsies using Fourier transform infrared imaging. RESULTS: Patients that received placebo exhibited increased mineral maturity/crystallinity and collagen cross-link ratio after 3 and 5 years compared with baseline values. On the contrary, patients that received risedronate retained baseline values in both bone material indices throughout. A more spatially detailed analysis revealed that this was achieved mainly through beneficial effects on active bone-forming areas. Surprisingly, patients that received risedronate achieved premenopausal values at bone-forming areas in both indices after 5 years of treatment. CONCLUSION: Long-term treatment with risedronate affects bone material properties (mineral maturity/crystallinity and collagen cross-link ratio) and arrests the tissue aging apparent in untreated osteoporosis. These changes at the material level of the bone matrix may contributeto risedronate's rapid and sustained antifracture efficacy in osteoporotic patients.
机译：评估了利塞膦酸盐对骨质疏松妇女三重triple活检中骨矿物质成熟度/结晶度和胶原蛋白交联比的长期影响。在这项双盲研究中，利塞膦酸盐治疗3年和5年可阻止未经治疗的骨质疏松症和其他抗吸收剂治疗的骨质疏松症所遇到的组织老化。该作用可能有助于利塞膦酸盐的抗骨折功效。简介：Risedronate被广泛用于骨质疏松症的治疗。它减少了骨转换，增加了BMD，并降低了骨折风险。迄今为止，尚无关于利塞膦酸盐对人体骨材料特性的长期影响的数据。材料和方法：参加VERT-NA试验的骨质疏松妇女接受利塞膦酸盐（5毫克/天，口服）或安慰剂治疗长达5年。所有受试者均接受钙。如果基线时缺乏维生素D，他们还将接受维生素D的补充。在基线，3年和5年时，从这些受试者的一个子集中收集了三次活检。使用傅里叶变换红外成像法在这些活检组织中测量矿物质的成熟度/结晶度和胶原蛋白的交联比。结果：与基线值相比，接受安慰剂的患者在3年和5年后表现出更高的矿物质成熟度/结晶度和胶原蛋白交联比。相反，接受瑞斯膦酸盐治疗的患者在整个两个骨质指数中均保持基线值。在空间上进行的更详细的分析表明，这主要是通过对活跃的骨形成区域产生有益影响而实现的。令人惊讶的是，接受瑞斯膦酸盐治疗的患者在治疗5年后，在两个指标上均达到了骨形成区域的绝经前值。结论：利塞膦酸盐的长期治疗会影响骨材料的性质（矿物质的成熟度/结晶度和胶原蛋白的交联比），并阻止未经治疗的骨质疏松症中明显的组织老化。在骨质疏松症患者中，骨基质材料水平的这些变化可能有助于利塞膦酸盐的快速和持续抗骨折功效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号